Table 2. Correlations between serum or tissue AFP and clinicopathological variables.
| Variables | Serum AFP concentration (ng/mL) | P | Tissue AFP expression (IHC) | P | ||
|---|---|---|---|---|---|---|
| AFP <92.33, N=165 (66.5%) | AFP ≥92.33, N=83 (33.55%) | AFP negative, N=174 (70.2%) | AFP positive, N=74 (29.8%) | |||
| Age (years), n (%) | ||||||
| <60 | 99 (60.0) | 59 (71.1) | 0.087 | 105 (60.3) | 53 (71.6) | 0.091 |
| ≥60 | 66 (40.0) | 24 (28.9) | 69 (39.7) | 21 (28.4) | ||
| Sex, n (%) | ||||||
| Male | 141 (85.5) | 63 (75.9) | 0.063 | 147 (84.5) | 57 (77.0) | 0.160 |
| Female | 24 (14.5) | 20 (24.1) | 27 (15.5) | 17 (23.0) | ||
| HBV, n (%) | ||||||
| Positive | 110 (66.7) | 68 (81.9) | 0.012 | 116 (66.7) | 69 (93.2) | 0.006 |
| Negative | 55 (33.3) | 15 (18.1) | 58 (33.3) | 21 (6.8) | ||
| HCV, n (%) | ||||||
| Positive | 11 (6.7) | 5 (6.1) | 0.846 | 13 (7.5) | 3 (4.1) | 0.316 |
| Negative | 154 (93.3) | 78 (93.9) | 161 (92.5) | 71 (95.9) | ||
| Tumor number, n (%) | ||||||
| Single | 154 (93.3) | 78 (93.9) | 0.846 | 159 (91.4) | 73 (98.6) | 0.033 |
| Multiple | 11 (6.7) | 5 (6.1) | 15 (8.6) | 1 (1.4) | ||
| Tumor size (cm), n (%) | ||||||
| <5 | 124 (75.2) | 51 (61.4) | 0.025 | 122 (70.1) | 53 (71.6) | 0.812 |
| ≥5 | 41 (24.8) | 32 (38.6) | 52 (29.9) | 21 (28.4) | ||
| BCLC stage, n (%) | ||||||
| 0 | 26 (15.8) | 9 (10.8) | 0.062 | 23 (13.2) | 12 (16.2) | 0.700 |
| A | 97 (58.8) | 41 (49.4) | 96 (55.2) | 42 (56.8) | ||
| B | 42 (25.4) | 33 (39.8) | 55 (31.6) | 20 (27.0) | ||
| Histological grade, n (%) | ||||||
| I | 29 (17.6) | 3 (3.6) | 0.001 | 31 (17.8) | 1 (1.4) | <0.001 |
| II | 97 (58.8) | 46 (55.4) | 101 (58.0) | 42 (56.8) | ||
| III | 39 (23.6) | 34 (41.0) | 42 (24.2) | 31 (41.8) | ||
AFP, alpha-fetoprotein; IHC, immunohistochemistry; HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona clinic liver cancer.